181 related articles for article (PubMed ID: 18644978)
1. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.
Letard S; Yang Y; Hanssens K; Palmérini F; Leventhal PS; Guéry S; Moussy A; Kinet JP; Hermine O; Dubreuil P
Mol Cancer Res; 2008 Jul; 6(7):1137-45. PubMed ID: 18644978
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction by several KIT juxtamembrane domain mutations.
Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
[TBL] [Abstract][Full Text] [Related]
3. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
[TBL] [Abstract][Full Text] [Related]
4. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
5. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
[TBL] [Abstract][Full Text] [Related]
7. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
8. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
10. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.
Jin Y; Chen Q; Shi X; Lu Z; Cheng C; Lai Y; Zheng Q; Pan J
Cancer Sci; 2009 Jul; 100(7):1335-43. PubMed ID: 19383029
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
[TBL] [Abstract][Full Text] [Related]
12. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.
Molderings GJ; Kolck UW; Scheurlen C; Brüss M; Homann J; Von Kügelgen I
Scand J Gastroenterol; 2007 Sep; 42(9):1045-53. PubMed ID: 17710669
[TBL] [Abstract][Full Text] [Related]
13. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.
Tabone-Eglinger S; Subra F; El Sayadi H; Alberti L; Tabone E; Michot JP; Théou-Anton N; Lemoine A; Blay JY; Emile JF
Clin Cancer Res; 2008 Apr; 14(8):2285-94. PubMed ID: 18413817
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
16. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
17. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.
Usher SG; Radford AD; Villiers EJ; Blackwood L
Exp Hematol; 2009 Jan; 37(1):65-77. PubMed ID: 18977066
[TBL] [Abstract][Full Text] [Related]
18. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
19. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
[TBL] [Abstract][Full Text] [Related]
20. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.
Wasag B; Niedoszytko M; Piskorz A; Lange M; Renke J; Jassem E; Biernat W; Debiec-Rychter M; Limon J
Exp Hematol; 2011 Aug; 39(8):859-65.e2. PubMed ID: 21689725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
